β2 adrenergic receptor, protein kinase A (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in Alzheimer disease models.
about
Successful therapies for Alzheimer's disease: why so many in animal models and none in humans?Dexmedetomidine increases tau phosphorylation under normothermic conditions in vivo and in vitro.Administration of a selective β2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's diseaseAmyloid β production is regulated by β2-adrenergic signaling-mediated post-translational modifications of the ryanodine receptor.Genetic suppression of β2-adrenergic receptors ameliorates tau pathology in a mouse model of tauopathies.Aβ1-42 monomers or oligomers have different effects on autophagy and apoptosisIsoform-specific interactions between meprin metalloproteases and the catalytic subunit of protein kinase A: significance in acute and chronic kidney injury.Transcriptomic analysis of the effects of a fish oil enriched diet on murine brains.c-Jun N-terminal kinase 3 expression in the retina of ocular hypertension mice: a possible target to reduce ganglion cell apoptosisNoradrenergic dysfunction in Alzheimer's disease.The importance of tau phosphorylation for neurodegenerative diseasesβ-Arrestins as potential therapeutic targets for Alzheimer's disease.The Binding Receptors of Aβ: an Alternative Therapeutic Target for Alzheimer's Disease.Compromised MAPK signaling in human diseases: an update.Stress-Induced Synaptic Dysfunction and Neurotransmitter Release in Alzheimer's Disease: Can Neurotransmitters and Neuromodulators be Potential Therapeutic Targets?Locus Ceruleus Norepinephrine Release: A Central Regulator of CNS Spatio-Temporal Activation?Ca(2+)/calmodulin-dependent protein kinase II interacts with group I metabotropic glutamate and facilitates receptor endocytosis and ERK1/2 signaling: role of β-amyloid.Derailed intraneuronal signalling drives pathogenesis in sporadic and familial Alzheimer's disease.Risperidone and aripiprazole alleviate prenatal valproic acid-induced abnormalities in behaviors and dendritic spine density in mice.Large-scale analysis of posttranslational modifications in the hippocampus of patients with Alzheimer's disease using pI shift and label-free quantification without enrichment.Phosphoinositides: Two-Path Signaling in Neuronal Response to Oligomeric Amyloid β Peptide.Enriched environment enhances β-adrenergic signaling to prevent microglia inflammation by amyloid-βEarly Life Stress and Epigenetics in Late-onset Alzheimer's Dementia: A Systematic ReviewNovel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation AssayThe Glymphatic System in Diabetes-Induced Dementia
P2860
Q26859305-AC71514D-E211-4F1B-B3A1-4685687471A1Q27307725-105D16A0-9EFC-4302-8A87-BFDF12322FA0Q27307852-5E643D23-B049-4FC5-A907-F934711DB03DQ33806103-72475CFA-293C-4ABC-A94B-C8F917862EDFQ33847602-B7C44B6F-A085-47CB-8425-97E053CF102AQ34344718-2E790DF3-F1A1-4F9F-BE0F-6A9F5DCCF370Q34801085-B6C20D96-738E-4CD8-B36F-111A7A07BBD7Q35121792-AF2DFBCD-E44F-4967-90BF-24F9597BE1FFQ35403481-3AAB4717-7D90-48A7-B260-A9C1FAC2C819Q35749478-C632337B-3357-4CE7-B722-DC228056A588Q36968220-19239612-34F6-4211-8B14-B1EEC7CCA353Q38107149-F87DAD70-83A4-4CE6-86A6-7B42B6064885Q38281324-63092505-C152-4D07-8049-CF3EF2737C05Q38359194-3A76BA2E-FB67-4681-AA97-0025E0BD389EQ38962792-E29225CB-43AD-4354-A52B-355BA40776E3Q39402128-0C408310-FF13-41DE-B20A-3508ED5FDAC1Q41811634-0B9053E5-92C9-411A-A04C-0DD0737AEF4FQ42872730-369B368D-546B-42D8-8641-7C4E6D6FD636Q47745710-29597BCC-49EB-4E66-ABD8-C59427A1D7EBQ48606333-D29848AF-11C4-49C3-8985-2FE846CCC78CQ53121718-87067FF2-A278-4687-B635-04E8F58C78ACQ57464744-CD386538-F79C-4BCB-A484-C98FCA6E4C4BQ58549216-6FF79E7A-7D38-4F7D-BEC8-82A562983AABQ58696563-576A4454-3EAA-4283-8910-ED871A09EBBFQ59133635-B5906E9D-3507-48F0-95A9-A21985F35F74
P2860
β2 adrenergic receptor, protein kinase A (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in Alzheimer disease models.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
β2 adrenergic receptor, protei ...... y in Alzheimer disease models.
@ast
β2 adrenergic receptor, protei ...... y in Alzheimer disease models.
@en
type
label
β2 adrenergic receptor, protei ...... y in Alzheimer disease models.
@ast
β2 adrenergic receptor, protei ...... y in Alzheimer disease models.
@en
prefLabel
β2 adrenergic receptor, protei ...... y in Alzheimer disease models.
@ast
β2 adrenergic receptor, protei ...... y in Alzheimer disease models.
@en
P2093
P2860
P356
P1476
β2 adrenergic receptor, protei ...... y in Alzheimer disease models.
@en
P2093
Benedict Igwe
Dayong Wang
Elena V Wisely
Johannes W Hell
Salvatore Oddo
Yang K Xiang
P2860
P304
10298-10307
P356
10.1074/JBC.M112.415141
P407
P50
P577
2013-02-19T00:00:00Z